MARKET

HZNP

HZNP

Horizon Therapeutics Plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

57.23
-0.77
-1.33%
After Hours: 57.23 0 0.00% 16:41 07/10 EDT
OPEN
57.74
PREV CLOSE
58.00
HIGH
57.98
LOW
56.34
VOLUME
2.22M
TURNOVER
--
52 WEEK HIGH
59.21
52 WEEK LOW
22.81
MARKET CAP
10.92B
P/E (TTM)
20.19
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average HZNP stock price target is 53.50 with a high estimate of 63.00 and a low estimate of 42.00.

EPS

HZNP News

More
The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 9) Affimed NV (NASDAQ: AFMD)
Benzinga · 16h ago
Horizon Therapeutics Announces Centers For Medicare & Medicaid Services Issues Permanent J-Code For TEPEZZA Effective Oct. 1, 2020
DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (NASDAQ:HZNP) today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a permanent, product-specific Healthcare Common Procedure
Benzinga · 1d ago
Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for TEPEZZA® (teprotumumab-trbw) Effective Oct. 1, 2020
Horizon Therapeutics announced that the U.S. Centers for Medicare and Medicaid Services has assigned a permanent J-code (J3241) for TEPEZZA.
Business Wire · 1d ago
Acer Therapeutics rallies on encouraging ACER-001 data
Seeking Alpha - Article · 1d ago
HemoShear Therapeutics Achieves Milestone in Exclusive Drug Discovery Collaboration with Horizon Therapeutics in Gout
HemoShear Therapeutics, LLC, a privately held clinical stage biotechnology company, has achieved a research milestone in its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP) to discover and develop novel therapeutics for gout. In fewer than 18 months
PR Newswire · 1d ago
Why These 3 Pharma Stocks Are Outplaying 90% Of The Stock Market
Investor's Business Daily · 2d ago
Were Hedge Funds Right About Horizon Therapeutics Public Limited Company (HZNP) ?
Insider Monkey · 3d ago
Horizon Therapeutics Looks Fairly Valued After Recent Run-Up
Seeking Alpha - Article · 07/03 05:24

Industry

Pharmaceuticals
-0.31%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About HZNP

Horizon Therapeutics plc, formerly Horizon Pharma plc, is a rare disease biopharmaceutical company. The Company is focused on researching, developing and commercializing medicines that address needs for people impacted by rare and rheumatic diseases. The Company markets approximately 10 medicines, of which 6 are for rare and rheumatic diseases. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).
More

Webull offers kinds of Horizon Therapeutics PLC stock information, including NASDAQ:HZNP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HZNP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HZNP stock methods without spending real money on the virtual paper trading platform.